GT20029 / Kintor Pharma - LARVOL DELTA

To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males (clinicaltrials.gov) - P2 | N=180 | Completed | Sponsor: Suzhou Kintor Pharmaceutical Inc,

New P2 trial • Alopecia • Dermatology • Immunology

Efficacy and Safety of Topical GT20029 Solution in Chinese Adult Males with Androgenetic Alopecia: Results of a Randomized, Double-blind, Vehicle-controlled, Multicenter Phase II Study (EADV 2024) - "Current standard of pharmaceutical care includes topical 5% minoxidil and oral finasteride (2). As the first PROTAC in dermatological disorders, topical GT20029 has exhibited promising efficacy in male AGA as well as great safety profile. Furthermore, less frequent dosing may provide a more convenient treatment option for male AGA patients."

Clinical • P2 data • Acne Vulgaris • Alopecia • Dermatitis • Immunology • Pruritus • Sexual Disorders • Targeted Protein Degradation • AR

To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: Suzhou Kintor Pharmaceutical Inc,

New P1 trial • Acne Vulgaris • Alopecia • Dermatology • Immunology

Safety, Tolerability and Pharmacokinetics of GT20029 Gel and GT20029 Solution in Healthy Subjects (EADV 2023) - "Overall, HVs who received a single application of GT20029 gel (1, 2, 5 and 10 mg) or 14-days topical GT20029 gel (2 mg once per day [QD], 2mg twice per day [BID], 5mg QD, 5mg BID, 10 mg QD) or solution (5mg QD, 10mg QD and 20 mg QD) showed low system exposure and good safety. Combined with the obtained PK characteristics and overall safety data, it is recommended to explore the safety and efficacy of multi-dose application of GT20029 solution (5 mg 0.5% QD, 10 mg 1.0% QD) in follow-up studies. Page 2** of 2**"

Clinical • PK/PD data • Acne Vulgaris • Alopecia • Dermatology • Pruritus • Targeted Protein Degradation • AR

Safety, Tolerability and Pharmacokinetics (PK) of GT20029 Following Topical Single Ascending Dose (SAD) Administration in Healthy Volunteers and Multiple Ascending Dose (MAD) Administration in Subjects with Androgenetic Alopecia (AGA) or Acne (EADV 2023) - "Overall GT20029 was safe and well tolerated. No significant safety concerns were identified in the study. PK parameters such as AUC, Cmax, Tmax, t1/2 were assessed, however, following topical administration, systemic exposure of GT20029 was low."

Clinical • PK/PD data • Acne Vulgaris • Alopecia • Pain • Pruritus • Targeted Protein Degradation • AR

Safety, Tolerability and Pharmacokinetics of GT20029 Gel and GT20029 Solution in Healthy Subjects (EADV 2023) - "Overall, HVs who received a single application of GT20029 gel (1, 2, 5 and 10 mg) or 14-days topical GT20029 gel (2 mg QD, 2mg BID, 5mg QD, 5mg BID, 10 mg QD) or solution (5mg QD, 10mg QD and 20 mg QD) showed low system exposure and good safety. Combined with the obtained PK characteristics and overall safety data, it is recommended to explore the safety and efficacy of multi-dose application of GT20029 solution (5 mg 0.5% QD, 10 mg 1.0% QD) in follow-up studies. Page 2** of 2**"

Clinical • PK/PD data • Acne Vulgaris • Alopecia • Dermatology • Pruritus • Targeted Protein Degradation • AR

Safety, Tolerability and Pharmacokinetics (PK) of GT20029 Following Topical Single Ascending Dose (SAD) Administration in Healthy Volunteers and Multiple Ascending Dose (MAD) Administration in Subjects with Androgenetic Alopecia (AGA) or Acne (EADV 2023) - "Overall GT20029 was safe and well tolerated. No significant safety concerns were identified in the study. PK parameters such as AUC, Cmax, Tmax, t1/2 were assessed, however, following topical administration, systemic exposure of GT20029 was low."

Clinical • PK/PD data • Acne Vulgaris • Alopecia • Pain • Pruritus • Targeted Protein Degradation • AR

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 (clinicaltrials.gov) - P1 | N=120 | Completed | Sponsor: Suzhou Kintor Pharmaceutical Inc, | Recruiting ➔ Completed

Trial completion • Acne Vulgaris • Alopecia • Dermatology

What's New in Therapy for Male Androgenetic Alopecia? (PubMed, Am J Clin Dermatol) - "Mesotherapy with dutasteride has also become more widespread recently, although evidence of its effectiveness is limited to retrospective studies in real clinical practice. The use of oral minoxidil in androgenetic alopecia has not been approved by the FDA, however several clinical studies have shown that it is an effective treatment option...Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor, while cetirizine is another topical option with some initial promising results. Furthermore, according to isolated studies with heterogeneous treatment schemes, the use of botulinum toxin in the scalp might improve androgenetic alopecia, and lastly, scalp threading might increase the total hair count as growth factors are released during implantation."

Journal • Alopecia • Dermatology • AR

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 (clinicaltrials.gov) - P1 | N=152 | Recruiting | Sponsor: Suzhou Kintor Pharmaceutical Inc,

New P1 trial • Acne Vulgaris • Alopecia • Dermatology